Changes of aqueous vascular endothelial growth factor and interleukin‐6 after intravitreal triamcinolone for branch retinal vein occlusion
Authors:
- 1 December 2008
- journal article
- research article
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 36 (9) , 831-835
Abstract
Background: To investigate sequential changes of aqueous vascular endothelial growth factor (VEGF) and interleukin (IL)‐6 in macular oedema secondary to branch retinal vein occlusion after single intravitreal injection of triamcinolone acetonide (IVTA).Methods: We recruited 10 healthy controls and 30 patients at Chonnam National University Hospital, Gwangju, Korea. Aqueous and plasma levels of VEGF and IL‐6 were measured by enzyme‐linked immunosorbent assay at the time of IVTA and 3 months later. Non‐response to IVTA was defined as showing persistent macular oedema based on a reduction of central macular thickness by less than 20% from baseline measurements by optical coherence tomography and vision improvement by less than 0.3 logMAR. Fluorescein angiography was performed 6 months after IVTA. We compared aqueous levels of VEGF and IL‐6 between responders and non‐responders.Results: The aqueous levels of VEGF and IL‐6 were significantly higher in 12 non‐responders than in 18 responders at baseline measurements (511 ± 245 pg/mL vs. 230 ± 108 pg/mL, P < 0.001; 38 ± 31 pg/mL vs. 16 ± 13 pg/mL, P < 0.001, respectively). Aqueous levels of VEGF were still higher in non‐responders (312 ± 64 pg/mL) 3 months after IVTA, and aqueous levels of VEGF in responders returned to normal (86 ± 21 pg/mL, P < 0.001). Aqueous levels of IL‐6 normalized in all patients 3 months after IVTA. Fluorescein angiography revealed that non‐responders showed higher frequencies of macular ischaemia and ischaemic branch retinal vein occlusion.Conclusions: IL‐6‐independent VEGF secretion may contribute to persistent macular oedema associated with ischaemic BRVO after IVTA.Keywords
This publication has 17 references indexed in Scilit:
- INTRAVITREAL BEVACIZUMAB (AVASTIN) IN THE TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONRetina, 2007
- Intravitreal Triamcinolone for the Treatment of Ischemic Macular Edema Associated With Branch Retinal Vein OcclusionAmerican Journal of Ophthalmology, 2006
- INTRAVITREAL TRIAMCINOLONE INJECTION FOR TREATMENT OF MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSIONRetina, 2005
- Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseasesProgress in Retinal and Eye Research, 2005
- Pathogenesis of Macular Edema With Branch Retinal Vein Occlusion and Intraocular Levels of Vascular Endothelial Growth Factor and Interleukin-6American Journal of Ophthalmology, 2005
- Intravitreal triamcinolone acetonide in patients with macular oedema due to branch retinal vein occlusion: a pilot studyActa Ophthalmologica Scandinavica, 2005
- Branch retinal vein occlusion treated by intravitreal triamcinolone acetonideEye, 2004
- Interleukin 6 Induces the Expression of Vascular Endothelial Growth FactorJournal of Biological Chemistry, 1996
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994
- IL-6 increases endothelial permeability in vitroEndocrinology, 1992